# Arcangelo Liso

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 102 papers | 6,576 citations | 33 h-index | 80 g-index |
| 108 ext. papers | 7,319 ext. citations | 6.6 avg, IF | 4.55 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 102 | Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *New England Journal of Medicine*, **2005**, 352, 254-66 | 59.2 | 1374 |
| 101 | BRAF mutations in hairy-cell leukemia. *New England Journal of Medicine*, **2011**, 364, 2305-15 | 59.2 | 791 |
| 100 | Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 3945-50 | 11.5 | 426 |
| 99 | Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma: Feasibility Study. *Blood*, **1999**, 93, 2411-2419 | 2.2 | 360 |
| 98 | Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. *Blood*, **2006**, 107, 4514-23 | 2.2 | 201 |
| 97 | Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). *Lancet, The*, **2004**, 363, 1869-70 | 40 | 194 |
| 96 | Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. *Blood*, **2011**, 118, 6153-63 | 2.2 | 191 |
| 95 | Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. *Blood*, **2011**, 117, 1109-20 | 2.2 | 178 |
| 94 | Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. *Journal of Experimental Medicine*, **2004**, 199, 59-68 | 16.6 | 161 |
| 93 | Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. *Leukemia*, **2009**, 23, 1731-43 | 10.7 | 156 |
| 92 | Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. *Haematologica*, **2007**, 92, 519-32 | 6.6 | 156 |
| 91 | Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. *Blood*, **2006**, 108, 1999-2005 | 2.2 | 146 |
| 90 | T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. *Blood*, **2004**, 104, 3722-30 | 2.2 | 128 |
| 89 | Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. *Leukemia*, **2005**, 19, 1760-7 | 10.7 | 124 |
| 88 | Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2000**, 6, 621-7 | 4.7 | 122 |
| 87 | Immunocytochemical Diagnosis of Acute Promyelocytic Leukemia (M3) With the Monoclonal Antibody PG-M3 (Anti-PML). *Blood*, **1997**, 90, 4046-4053 | 2.2 | 113 |
| 86 | Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. *Leukemia*, **2007**, 21, 1566-70 | 10.7 | 97 |

| | | | |
|---|---|---|---|
| 85 | PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. *Cancer Research*, **2004**, 64, 7399-404 | 10.1 | 89 |
| 84 | Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. *Acta Haematologica*, **2003**, 110, 29-32 | 2.7 | 86 |
| 83 | CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. *Blood*, **2010**, 116, 3907-22 | 2.2 | 83 |
| 82 | Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. *Blood*, **2006**, 108, 4146-55 | 2.2 | 82 |
| 81 | Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. *Cancer Research*, **2007**, 67, 6230-7 | 10.1 | 81 |
| 80 | Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. *Bone Marrow Transplantation*, **2006**, 37, 719-24 | 4.4 | 81 |
| 79 | Evolving concepts in the pathogenesis of hairy-cell leukaemia. *Nature Reviews Cancer*, **2006**, 6, 437-48 | 31.3 | 79 |
| 78 | Abnormal pattern of lymphocyte subpopulations in the endometrium of infertile women with chronic endometritis. *American Journal of Reproductive Immunology*, **2009**, 61, 322-9 | 3.8 | 69 |
| 77 | Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. *Blood*, **2006**, 108, 1013-20 | 2.2 | 59 |
| 76 | Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. *Translational Research*, **2005**, 145, 212-20 | | 53 |
| 75 | FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. *Annals of Hematology*, **2005**, 84, 792-5 | 3 | 47 |
| 74 | Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. *Haematologica*, **2008**, 93, 775-9 | 6.6 | 42 |
| 73 | Normal percentage of CD56bright natural killer cells in young patients with a history of repeated unexplained implantation failure after in vitro fertilization cycles. *Fertility and Sterility*, **2007**, 88, 990-3 | 4.8 | 41 |
| 72 | Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. *Leukemia*, **2006**, 20, 368-71 | 10.7 | 37 |
| 71 | In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. *Leukemia*, **2008**, 22, 1285-9 | 10.7 | 36 |
| 70 | Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. *Blood*, **2005**, 105, 2812-20 | 2.2 | 34 |
| 69 | Bcl-6 protein expression in normal and neoplastic lymphoid tissue. *Annals of Oncology*, **1997**, 8, S101-S104 | 10.3 | 33 |
| 68 | Reduced percentage of natural killer cells associated with impaired cytokine network in the secretory endometrium of infertile women with polycystic ovary syndrome. *Fertility and Sterility*, **2010**, 94, 2222-7, 2227.e1-3 | 4.8 | 28 |

| | | | |
|---|---|---|---|
| 67 | Good and poor CD34+ cells mobilization in acute leukemia: analysis of factors affecting the yield of progenitor cells. *Bone Marrow Transplantation*, **2004**, 33, 1083-7 | 4.4 | 28 |
| 66 | Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 25 |
| 65 | Pneumonia in acute leukemia patients during induction therapy: experience in a single institution. *Leukemia and Lymphoma*, **2003**, 44, 97-101 | 1.9 | 23 |
| 64 | Autoimmune myelofibrosis: report of three cases and review of the literature. *Leukemia and Lymphoma*, **2004**, 45, 561-6 | 1.9 | 23 |
| 63 | A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome. *Cancer Genetics and Cytogenetics*, **2004**, 150, 81-5 | | 22 |
| 62 | Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML. *Leukemia*, **2008**, 22, 195-8 | 10.7 | 21 |
| 61 | A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia. *Leukemia*, **2008**, 22, 2285-8 | 10.7 | 20 |
| 60 | A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). *Haematologica*, **2008**, 93, 1219-26 | 6.6 | 20 |
| 59 | Computational modeling of the immune response to tumor antigens. *Journal of Theoretical Biology*, **2005**, 237, 390-400 | 2.3 | 20 |
| 58 | Insertions generating the 5′RUNX1/3′CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints. *Genes Chromosomes and Cancer*, **2004**, 41, 86-91 | 5 | 19 |
| 57 | Linking surgical specimen length and examined lymph nodes in colorectal cancer patients. *European Journal of Surgical Oncology*, **2016**, 42, 260-5 | 3.6 | 17 |
| 56 | Preliminary evidence for high anti-PLAC1 antibody levels in infertile patients with repeated unexplained implantation failure. *Placenta*, **2013**, 34, 335-9 | 3.4 | 17 |
| 55 | Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules. *Leukemia*, **2008**, 22, 424-6 | 10.7 | 17 |
| 54 | Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. *Cancer Research*, **2017**, 77, 3685-3699 | 10.1 | 16 |
| 53 | Seasonal variation in the month of birth in patients with skin cancer. *British Journal of Cancer*, **2014**, 111, 1810-3 | 8.7 | 16 |
| 52 | Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes. *Leukemia and Lymphoma*, **2004**, 45, 689-94 | 1.9 | 16 |
| 51 | Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. *British Journal of Haematology*, **2011**, 152, 365 | 4.5 | 15 |
| 50 | Early and long-term engraftment after autologous peripheral stem cell transplantation in acute myeloid leukemia patients. *Acta Haematologica*, **2006**, 116, 229-37 | 2.7 | 15 |

| | | | |
|---|---|---|---|
| 49 | Donor Selection for Allogenic Hemopoietic Stem Cell Transplantation: Clinical and Ethical Considerations. *Stem Cells International*, **2017**, 2017, 5250790 | 5 | 14 |
| 48 | Insulin-Like Growth Factor Binding Protein 6 in Rheumatoid Arthritis: A Possible Novel Chemotactic Factor?. *Frontiers in Immunology*, **2017**, 8, 554 | 8.4 | 14 |
| 47 | NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?. *Leukemia*, **2008**, 22, 1459-63 | 10.7 | 14 |
| 46 | Haploidentical peripheral-blood stem-cell transplantation for ALK-positive anaplastic large-cell lymphoma. *Lancet Oncology, The*, **2004**, 5, 127-8 | 21.7 | 14 |
| 45 | Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of. *Oncotarget*, **2017**, 8, 60826-60840 | 3.3 | 14 |
| 44 | Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment. *Medical Oncology*, **2003**, 20, 389-96 | 3.7 | 13 |
| 43 | Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature. *Leukemia and Lymphoma*, **2002**, 43, 2217-20 | 1.9 | 11 |
| 42 | Submicroscopic deletions in an acute myeloid leukemia case with a four-way t(8;11;16;21). *Leukemia Research*, **2005**, 29, 855-8 | 2.7 | 10 |
| 41 | From fever to immunity: A new role for IGFBP-6?. *Journal of Cellular and Molecular Medicine*, **2018**, 22, 4588-4596 | 5.6 | 9 |
| 40 | Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy. *Lancet Oncology, The*, **2004**, 5, 64-5 | 21.7 | 9 |
| 39 | Evaluation of the Potential of Biofilm Formation of subsp. and as Competitive Biocontrol Agents Against Pathogenic and Food Spoilage Bacteria. *Microorganisms*, **2020**, 8, | 4.9 | 8 |
| 38 | Hematopoietic Stem Cell Transplantation: A Bioethical Lens. *Stem Cells International*, **2017**, 2017, 1286246 | 5 | 8 |
| 37 | Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma. *Oncology Letters*, **2013**, 5, 975-977 | 2.6 | 8 |
| 36 | The role of computational models of the immune system in designing vaccination strategies. *Immunopharmacology and Immunotoxicology*, **2005**, 27, 417-32 | 3.2 | 8 |
| 35 | Modulatory effects of mycobacterial heat-shock protein 70 in DNA vaccination against lymphoma. *Haematologica*, **2005**, 90, 60-5 | 6.6 | 8 |
| 34 | Immunophenotypic and molecular features of RUNX1-like acute myeloid leukemias. *European Journal of Haematology*, **2014**, 92, 121-6 | 3.8 | 7 |
| 33 | Non-treatment-related chronic myeloid leukemia as a second malignancy. *Leukemia Research*, **2004**, 28, 115-9 | 2.7 | 7 |
| 32 | Pericentric chromosome 8 inversion associated with the 5' RUNX1/3' CBFA2T1 gene in acute myeloid leukemia cases. *Annals of Hematology*, **2005**, 84, 245-9 | 3 | 7 |

| | | | |
|---|---|---|---|
| 31 | Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study. *Blood*, **1999**, 93, 2411-2419 | 2.2 | 7 |
| 30 | Insulin-like growth factor-6 (IGFBP-6) stimulates neutrophil oxidative burst, degranulation and chemotaxis. *Inflammation Research*, **2018**, 67, 107-109 | 7.2 | 7 |
| 29 | A chronic myelocytic leukemia case bearing deletions on the three chromosomes involved in a variant t(9;22;11). *Cancer Genetics and Cytogenetics*, **2004**, 148, 137-40 | | 6 |
| 28 | Selective Silencing of the NPM1 Mutant Protein and Apoptosis Induction upon ATRA In Vitro Treatment of AML Cells Carrying NPM1 Mutations.. *Blood*, **2007**, 110, 868-868 | 2.2 | 5 |
| 27 | Seasonal Variation in Skin Cancer Diagnosis. *Frontiers in Public Health*, **2016**, 4, 78 | 6 | 5 |
| 26 | Use of design of experiments to optimize the production of microbial probiotic biofilms. *PeerJ*, **2018**, 6, e4826 | 3.1 | 4 |
| 25 | Molecular cytogenetic study of instability at 1q21 approximately q32 in adult acute lymphoblastic leukemia. *Cancer Genetics and Cytogenetics*, **2005**, 156, 54-8 | | 4 |
| 24 | From Infection to Immunity: Understanding the Response to SARS-CoV2 Through Modeling. *Frontiers in Immunology*, **2021**, 12, 646972 | 8.4 | 4 |
| 23 | Insulin-Like Growth Factor Binding Protein 6 Is Secreted in Extracellular Vesicles upon Hyperthermia and Oxidative Stress in Dendritic Cells But Not in Monocytes. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 3 |
| 22 | Microscopic simulation in biology and medicine. *Current Medicinal Chemistry*, **2007**, 14, 625-37 | 4.3 | 3 |
| 21 | Seasonality of birth for skin melanoma deserves further investigation. *International Journal of Epidemiology*, **2017**, 46, 763-765 | 7.8 | 2 |
| 20 | The Crosstalk between GPR81/IGFBP6 Promotes Breast Cancer Progression by Modulating Lactate Metabolism and Oxidative Stress.. *Antioxidants*, **2022**, 11, | 7.1 | 2 |
| 19 | Febrile temperature reprograms by redox-mediated signaling the mitochondrial metabolic phenotype in monocyte-derived dendritic cells. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2018**, 1864, 685-699 | 6.9 | 2 |
| 18 | IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis.. *Aging*, **2021**, 13, 25055-25071 | 5.6 | 2 |
| 17 | PLAC1 immunization does not induce infertility in mice. *Immunotherapy*, **2017**, 9, 481-486 | 3.8 | 1 |
| 16 | Molecular cytogenetics characterization of a novel translocation involving chromosomes 17 and 19 in a Ph+ adult acute lymphoblastic leukaemia. *British Journal of Haematology*, **2002**, 119, 488-91 | 4.5 | 1 |
| 15 | Vaccine therapy of B cell malignancies: different strategies for a novel approach. *Leukemia and Lymphoma*, **2001**, 42, 881-9 | 1.9 | 1 |
| 14 | Evidence for CD34+ Hematopoietic Progenitor Cell Involvement in Acute Myeloid Leukemia with NPM1 Gene Mutation: Implications for the Cell of Origin. *Blood*, **2008**, 112, 307-307 | 2.2 | 1 |

# List of Publications

| | | | |
|---|---|---|---|
| 13 | Cohesin complex is a major player on the stage of leukemogenesis. *Stem Cell Investigation*, **2016**, 3, 18 | 5.1 | 1 |
| 12 | Genome-wide computational approach for the prediction of duplications generating protein localization signals. *Computers in Biology and Medicine*, **2012**, 42, 1091-7 | 7 | |
| 11 | The Significance of Purity: Leukaemias Involving the Erythroid Lineage. *Mediterranean Journal of Hematology and Infectious Diseases*, **2020**, 12, e2020077 | 3.2 | |
| 10 | Droplets generated from toilets during urination as a possible vehicle of carbapenem-resistant Klebsiella pneumoniae. *Antimicrobial Resistance and Infection Control*, **2021**, 10, 149 | 6.2 | |
| 9 | Tumor Protein D52 (TPD52): A Novel B Cell/Plasma Cell Molecule Identified through a Proteomic Approach and Characterized by Unique Expression Pattern and Ca2+-Dependent Association with Annexin VI.. *Blood*, **2004**, 104, 3652-3652 | 2.2 | |
| 8 | Heterogeneous Chromosomal Mechanisms Generating the 5?RUNX1/3?CBFA2T1 Gene in Acute Myeloid Leukemia.. *Blood*, **2004**, 104, 4272-4272 | 2.2 | |
| 7 | Exon-12 Nucleophosmin (NPM) Mutation and Aberrant Cytoplasmic Expression of NPM Protein in Leukemia Cell Line OCI-AML3.. *Blood*, **2005**, 106, 2376-2376 | 2.2 | |
| 6 | Mechanism of Altered Nucleo-Cytoplasmic Traffic of Nucleophosmin in Acute Myelogenous Leukemia Carrying Exon-12 NPM Mutations (NPMc+ AML).. *Blood*, **2005**, 106, 4396-4396 | 2.2 | |
| 5 | Extramedullary Infiltrates of AML: Biological and Clinical Features in a Single Centre Experience.. *Blood*, **2006**, 108, 4513-4513 | 2.2 | |
| 4 | One-Mutation Model Can Explain Age Incidence in AML Carrying Nucleophosmin (NPM1) Mutations.. *Blood*, **2007**, 110, 4312-4312 | 2.2 | |
| 3 | CXCR4 as a Predictor of Response in Acute Myeloid Leukemia. *Blood*, **2008**, 112, 2941-2941 | 2.2 | |
| 2 | Dissecting the Hierarchical Level of Hematopoietic Progenitors?Involvement in AML with NPM1 Gene Mutation and Their Engraftment Potential in Immunocompromised Mice.. *Blood*, **2009**, 114, 480-480 | 2.2 | |
| 1 | Differential and divergent activity of insulin-like growth factor binding protein 6 in platinum-sensitive versus platinum-resistant high-grade serous ovarian carcinoma cell lines.. *Oncology Letters*, **2022**, 23, 185 | 2.6 | |